Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2011

View Archived Issues

Phase I/II trial assesses gene therapy in X-linked chronic granulomatous disease / News in Context

ADOPT study compares apixaban and enoxaparin in medically ill patients

Selvita describes novel pim and haspin kinase inhibitors

Kowa begins long-term phase III trial of potential glaucoma treatment in Japan

Mitsubishi Tanabe Pharma presents highlights of second quarter of fiscal year 2011

Novel apoptosis inhibitors patented by Chinese PLA General Hospital

GlaxoSmithKline presents new AMPK activators

Companies collaborate on spinal muscular atrophy research

Novel orexin receptor antagonists emerge from R&D at Evotec

Kyoto Pharmaceutical describes new indoline derivatives

Hippocampal markers of stress susceptibility identified

FDA accepts Onyx Pharmaceuticals' NDA for carfilzomib

New indazoles with antiproliferative and/or apoptosis-inducing activity identified

Civitas Therapeutics receives Michael J. Fox Foundation grant to develop CVT-301

New anticancer compounds described by Merck & Co.

PET and MRI can be used to asses a marker of nociceptive activity

Advinus Therapeutics completes proof-of-concept study of GKM-001

Alnylam completes enrollment in phase IIb ALN-RSV01 study

Targovax to receive grant for phase II/III cancer vaccine study

Omthera Pharmaceuticals completes enrollment in EVOLVE study

Marina Biotech and Debiopharm select lead formulation for bladder cancer program

Talon Therapeutics enrolls first patient in phase III Marqibo study

Ablynx's phase I/II study of ALX-0061 advances

Merrimack Pharmaceuticals begins phase I study of MM-121 with multiple anticancer therapies

Dainippon Sumitomo Pharma files application in Japan for combination antihypertensive product

Idera Pharmaceuticals regains global rights to IMO-2055

Dainippon Sumitomo Pharma and Yoshitomiyakuhin to terminate antipsychotic drug copromotion agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026